Global pharma powerhouse Moderna is all set to unveil "groundbreaking" oral data on its investigational seasonal influenza vaccine, mRNA-1010, and its mRNA respiratory syncytial virus (RSV) vaccine, mRESVIA (mRNA-1345) in Germany later this month.

 

The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21.

 

The presentation, "Sequential administration of an mRNA-based seasonal influenza vaccine in older adults," reports on a post-hoc analysis of mRNA-1010’s safety and immune response in adults 50 and older who had previously received either mRNA-1010 or a licensed egg-based influenza vaccine.

 

With a median 23-month gap between doses, Moderna said, “Day 29 hemagglutination inhibition geometric mean fold rises for all three WHO-recommended influenza strains (A/H1N1, A/H3N2, B/Victoria) were similar in participants who received mRNA-1010 in P304, regardless of prior study vaccination assignment, and numerically higher compared to participants who received a licensed egg-based comparator in P304.”

 

Importantly, the company reported, “There were no increases in solicited adverse reactions or new safety concerns observed with sequential mRNA-1010 vaccination.”

 

mRNA-1010 is currently under review in the United States, Europe, Canada, and Australia, with additional submissions planned for 2026. Moderna expects “the first potential approvals for mRNA-1010 in 2026, subject to ongoing regulatory reviews.”

 

Moderna will also present interim findings from an ongoing Phase 3 study of mRESVIA in adults 60 and older, in a presentation titled "Safety and immunogenicity of RSV revaccination with mRNA-1345 after primary vaccination with protein-based vaccine."

 

The study evaluated mRESVIA as a heterologous revaccination dose more than 12 months after a primary dose of a licensed RSV protein-based vaccine. Moderna said, “The mRESVIA revaccination dose was well-tolerated, with no new safety concerns observed.”

 

Highlighting the broader implications, the company noted, “Together, these results suggest that revaccination with mRESVIA may restore protection comparable to primary dose levels, regardless of whether mRESVIA or a protein-based vaccine was used for a primary dose.”